Parse Biosciences Partners With Gencell Pharma For South American Expansion

Parse Biosciences, a prominent supplier of accessible and scalable single-cell sequencing solutions, announced today a partnership with Gencell Pharma, based in Bogotá, Colombia. This agreement aims to expand Parse’s presence in Colombia and throughout South America.

Alex Rosenberg, CEO and Co-Founder of Parse Biosciences, said, “Demand for Parse’s Evercode single cell sequencing solutions continues to grow in South America as the academic, biotech, and pharma communities discover their scalability and simplicity. Through this partnership with Gencell, we are empowering them to easily adopt the leading single cell sequencing technology.”

Under the company’s agreement with Gencell Pharma, South American researchers will gain comprehensive access to Parse’s single cell portfolio. This includes Evercode™ Whole Transcriptome, Evercode TCR, Evercode BCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, CRISPR Detect, and the Trailmaker data analysis solution. This agreement is part of Parse’s continued effort to introduce its products in important international markets, which are already accessible in India, Europe, Singapore, Israel, New Zealand, South Zealand, North America, and Australia.

Fabio Andres Zapata Gomez, Gencell Pharma CEO, commented “This partnership with Parse will bring single cell sequencing to a wide range of researchers in South America, all of whom will greatly benefit from its Evercode technology. We're excited to see what breakthroughs the scientific community in South America is able to achieve with these newly available tools.”